CaltechAUTHORS
  A Caltech Library Service

A cancer treatment based on synergy between anti-angiogenic and immune cell therapies

Soto-Ortiz, Luis (2016) A cancer treatment based on synergy between anti-angiogenic and immune cell therapies. Journal of Theoretical Biology, 394 . pp. 197-211. ISSN 0022-5193. https://resolver.caltech.edu/CaltechAUTHORS:20160208-154034961

Full text is not posted in this repository. Consult Related URLs below.

Use this Persistent URL to link to this item: https://resolver.caltech.edu/CaltechAUTHORS:20160208-154034961

Abstract

A mathematical model integrating tumor angiogenesis and tumor-targeted cytotoxicity by immune cells was developed to identify the therapeutic window of two distinct modes to treat cancer: (1) an anti-angiogenesis treatment based on the monoclonal antibody bevacizumab that targets tumor vasculature, and (2) immunotherapy involving the injection of unlicensed dendritic cells to boost the anti-tumor adaptive response. The angiogenic cytokine Vascular Endothelial Growth Factor (VEGF) contributes to the immunosuppressive tumor microenvironment, which is responsible for the short-lived therapeutic effect of cancer-targeted immunotherapy. The effect of immunosuppression on the width of the therapeutic window of each treatment was quantified. Experimental evidence has shown that neutralizing immunosuppressive cytokines results in an enhanced immune response against infections and chronic diseases. The model was used to determine treatment protocols involving the combination of anti-VEGF and unlicensed dendritic cell injections that enhance tumor regression. The model simulations predicted that the most effective method to treat tumors involves administering a series of biweekly anti-VEGF injections to disrupt angiogenic processes and limit tumor growth. The simulations also verified the hypothesis that reducing the concentration of the immunosuppressive factor VEGF prior to an injection of unlicensed dendritic cells enhances the cytotoxicity of CD8+ T cells and results in complete tumor elimination. Feasible treatment protocols for tumors that are diagnosed late and have grown to a relatively large size were identified.


Item Type:Article
Related URLs:
URLURL TypeDescription
http://dx.doi.org/10.1016/j.jtbi.2016.01.026DOIArticle
http://www.sciencedirect.com/science/article/pii/S002251931600059XPublisherArticle
Additional Information:© 2016 Elsevier Ltd.
Subject Keywords:Immunotherapy; Monoclonal antibody; VEGF; Mathematical modeling; Immunosuppression; Tumor angiogenesis
Record Number:CaltechAUTHORS:20160208-154034961
Persistent URL:https://resolver.caltech.edu/CaltechAUTHORS:20160208-154034961
Official Citation:Luis Soto-Ortiz, A cancer treatment based on synergy between anti-angiogenic and immune cell therapies, Journal of Theoretical Biology, Volume 394, 7 April 2016, Pages 197-211, ISSN 0022-5193, http://dx.doi.org/10.1016/j.jtbi.2016.01.026. (http://www.sciencedirect.com/science/article/pii/S002251931600059X)
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:64318
Collection:CaltechAUTHORS
Deposited By: Tony Diaz
Deposited On:09 Feb 2016 00:19
Last Modified:03 Oct 2019 09:36

Repository Staff Only: item control page